Floatz logo

Limertinib

Potentially Resectable

Shanghai Pulmonary Hospital, Shanghai, ChinaPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Potentially Resectable cohort.

Asset / SponsorPhaseRating
Sacituzumab Tirumotecan
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2CCC

Same molecule, other indications

Limertinib is also rated in:

PD-L1 PositiveDormant
CCC
Indicative ·
53 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
neoplasmDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →